{
    "nct_id": "NCT05695339",
    "official_title": "Phase I Open Label Clinical Trial Using Resiniferatoxin, A Non-Opioid Medication, For the Management of Refractory Morton's Neuroma Pain",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n\nBoth male and female participants are eligible for study evaluation. There are no exclusions for any racial/ethnic groups. Efforts will be made to extend accrual to a representative population. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Must be able to read, write, understand, and complete English-language study-related forms and adequately communicate in English.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged 18 and older.\n* In good general health as evidenced by medical history.\n* Diagnosed with one painful Morton s neuroma in the index foot\n* Has not attained satisfactory pain relief with conservative, oral analgesic and at least one kind of injection treatment for Morton s neuroma.\n* Exhibits moderate to severe foot pain due to the Morton s neuroma (average worst pain >= 5 on the 0-10 numeric pain rating scale NRS) as assessed verbally at >= 3 individual days during prescreening.\n* For females of reproductive potential who are sexually active: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one (1) month after administration of RTX.\n\nIf a female, be sterile (surgically or biologically) * or at least one year postmenopausal**, or have a monogamous partner who is surgically sterile, or have a same sex partner, or if in a heterosexual relationship, must agree to do the following for at least one month after receiving investigational product (IP):\n\n* Practice abstinence, or\n* Use at least one of the following medically acceptable methods of birth control:\n\n  * Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives (must have started a minimum of 1 full cycle, based on the subject s usual menstrual cycle period, before IP dose\n  * Intrauterine device\n  * Double-barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream).\n\n    * Defined as having had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; or having a congenital or acquired condition that prevents childbearing\n\n      * Defined as at least 12 months with no menses without an alternative medical cause) [can be confirmed with follicle stimulating hormone level (FSH) in the post-menopausal range (FSH levels >=40 milli international units/mL (mIU/mL) at Screening) if the subject is not on hormonal replacement therapy]\n* For males of reproductive potential who are sexually active: use of condoms or other methods to ensure effective contraception with partner for one (1) month after administration of (RTX).\n\nIf a male of reproductive potential, unless he has a same sex partner or a partner who is sterile or at least one year post-menopausal, must agree to do the following for at least one month after receiving IP\n\n* practice abstinence from heterosexual activity or\n* use (or have their partner use) acceptable contraception (see criterion above) during heterosexual activity\n\nMale study participants should not donate sperm for 3 months after RTX injection.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy or lactation.\n* Has a known allergy or hypersensitivity to chili peppers or capsaicin.\n* Has a known allergy to local anesthetics.\n* Has active or history of rheumatoid arthritis or peripheral neuropathy.\n* Has a prolonged baseline QTc interval exceeding 480 milliseconds.\n* Current presentation of other currently painful pathology of the same foot affected by Morton s neuroma, including, but not limited to, hallux valgus, plantar fasciitis, hammer toes, metatarsalgia, bursitis.\n* History of injection and/or ablation treatments treatment in the affected foot up to one month previous to study participation.\n* History of nerve excision due to Morton s neuroma in the location to be treated with RTX.\n* Active cutaneous disease, inflammation or infection at the anticipated site of study drug injection.\n* Has diabetes mellitus or peripheral vascular disease whether poorly managed or stable.\n* Has more than one Morton s neuroma in the index foot scheduled to receive the treatment intervention.\n* Other clinically significant condition that might interfere with study participation or greatly increases safety risk to the subject, as judged by the study investigator.\n* Concurrent treatment with another investigational drug or other intervention within last month.\n* Cognitive or language difficulties that would impair comprehension or completion of the assessment instruments.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}